×
About 52,322 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  24,781 results

An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cy...
https://doi.org/10.1080/17474086.2021.1938533
Expert Review of Hematology; Othman TA, Tenold ME et. al.

Jun 2nd, 2021 - Older patients with acute myeloid leukemia (AML) ineligible for conventional chemotherapy have historically received low-intensity treatments, if any, and have had dismal outcomes. Recent phase III data have demonstrated significant efficacy of ve...

Pre-transplant bone marrow cellularity and blood count recovery are not associated with...
https://doi.org/10.1111/ejh.13673
European Journal of Haematology; Novitzky-Basso I, Chen C et. al.

Jun 2nd, 2021 - Allogeneic hematopoietic cell transplantation (HCT) can be curative for acute myeloid leukemia (AML). Novel therapies may render patients' bone marrows hypocellular and lead to prolonged post-therapy pancytopenia. Patients' bone marrow cellularity...

Identification of RHOBTB2 aberration as an independent prognostic indicator in acute my...
https://doi.org/10.18632/aging.203087
Aging Liu P, Ma Q et. al.

Jun 2nd, 2021 - Rho-related BTB domain (RhoBTB) proteins belong to Rho guanosine triphosphatases (GTPases). Their putative role implicated in carcinogenesis has been supported by accumulating evidence. However, their expression pattern and potential role in acute...

Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and...
https://doi.org/10.1182/blood.2020010603
Blood Awada H, Durmaz A et. al.

Jun 2nd, 2021 - While genomic alterations drive the pathogenesis of acute myeloid leukemia (AML), traditional classifications are largely based on morphology and prototypic genetic founder lesions define only a small proportion of AML patients. The historical sub...

see more →

Guidelines  95 results

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 23rd, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Ivosidenib Plus Venetoclax With or Without Azacitidine for IDH1-Mutated AML
https://ascopost.com/news/june-2020/ivosidenib-plus-venetoclax-with-or-without-azacitidine-for-idh1-mutated-aml/

May 31st, 2020 - Combination therapy with the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosenidib plus the BCL2 inhibitor venetoclax with or without the chemotherapeutic agent azacitidine showed activity in patients with IDH1-mutated acute myeloid leukemia (AML...

AMG 330 Shows Promise in Treating Relapsed/Refractory AML
https://www.onclive.com/conference-coverage/asco-2020/amg-330-shows-promise-in-treating-relapsedrefractory-aml

May 29th, 2020 - Findings showed that AMG 330 was safe and tolerable in treating patients with relapsed or refractory acute myeloid leukemia (AML), with cytokine release syndrome (CRS) as the most frequent and expected adverse event (AE), according to preliminary ...

Palliative Care Improves Quality of Life in Patients With AML
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200172/full/

May 28th, 2020 - When patients with acute myeloid leukemia (AML) undergo intensive chemotherapy treatment, their quality of life (QoL) and mood are negatively affected. Areej El-Jawahri, MD, of Massachusetts General Hospital, presented the results of a multicenter...

High Expression of DOCK2 Indicates Good Prognosis in AML
https://www.jcancer.org/v10p6088.htm
Journal of Cancer; Hu N,et al

Oct 14th, 2019 - DOCK family proteins are evolutionarily conserved guanine nucleotide exchange factors for Rho GTPase with different cellular functions. It has been demonstrated that DOCK1 had adverse prognostic effect in acute myeloid leukemia (AML).

see more →

Drugs  59 results see all →

Clinicaltrials.gov  25,885 results

An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cy...
https://doi.org/10.1080/17474086.2021.1938533
Expert Review of Hematology; Othman TA, Tenold ME et. al.

Jun 2nd, 2021 - Older patients with acute myeloid leukemia (AML) ineligible for conventional chemotherapy have historically received low-intensity treatments, if any, and have had dismal outcomes. Recent phase III data have demonstrated significant efficacy of ve...

Pre-transplant bone marrow cellularity and blood count recovery are not associated with...
https://doi.org/10.1111/ejh.13673
European Journal of Haematology; Novitzky-Basso I, Chen C et. al.

Jun 2nd, 2021 - Allogeneic hematopoietic cell transplantation (HCT) can be curative for acute myeloid leukemia (AML). Novel therapies may render patients' bone marrows hypocellular and lead to prolonged post-therapy pancytopenia. Patients' bone marrow cellularity...

Identification of RHOBTB2 aberration as an independent prognostic indicator in acute my...
https://doi.org/10.18632/aging.203087
Aging Liu P, Ma Q et. al.

Jun 2nd, 2021 - Rho-related BTB domain (RhoBTB) proteins belong to Rho guanosine triphosphatases (GTPases). Their putative role implicated in carcinogenesis has been supported by accumulating evidence. However, their expression pattern and potential role in acute...

Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and...
https://doi.org/10.1182/blood.2020010603
Blood Awada H, Durmaz A et. al.

Jun 2nd, 2021 - While genomic alterations drive the pathogenesis of acute myeloid leukemia (AML), traditional classifications are largely based on morphology and prototypic genetic founder lesions define only a small proportion of AML patients. The historical sub...

see more →

News  1,497 results

Fast Five Quiz: Myelodysplastic Syndrome Presentation and Diagnosis
https://reference.medscape.com/viewarticle/950473

May 11th, 2021 - Myelodysplastic syndrome (MDS) is a group of related disorders that arise as the result of distorted hematopoietic stem cell function, inflammatory and innate immune deregulation, and multiple genomic events. These molecular alterations increase t...

Whole-Genome Sequencing Emerging for Routine Cancer Care
https://www.medscape.com/viewarticle/947261

Mar 10th, 2021 - Almost 20 years after the human genome was first mapped, whole-genome sequencing might finally be ready to enter routine cancer care. Researchers at Washington University in St. Louis, St. Louis, Missouri, are commercializing an automated sequenci...

FDA Places Clinical Hold on Sickle Cell Gene Therapy
https://www.medscape.com/viewarticle/946434

Feb 23rd, 2021 - Updated February 25, 2021 // Editor’s note: The original text has been corrected to accurately reflect the status of the patients with AML and MDS. The FDA placed a clinical hold yesterday on two gene therapy trials for sickle cell disease (SCD) a...

Fast Five Quiz: Myelodysplastic Syndrome
https://reference.medscape.com/viewarticle/943967

Jan 27th, 2021 - Myelodysplastic syndrome (MDS) is a group of related hematopoietic disorders characterized by peripheral blood cytopenias, abnormal blood cell development, and clonal genetic markers. Patients with MDS may present with clinical manifestations of a...

Leukemia: New Adverse Event With PARP Inhibitors in Cancer
https://www.medscape.com/viewarticle/943743

Jan 6th, 2021 - A new adverse event has been reported for PARP inhibitor drugs used in the treatment of cancer: the risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), both of which have a high mortality rate.   PARP inhibitors are...

see more →

Patient Education  5 results see all →